Moody's Rating Upgrade for ICU Medical
Moody's Investors Service upgraded ICU Medical Inc.'s corporate family rating, probability of default rating, and senior secured bank credit facilities to Ba3 from B1, while keeping the outlook stable. The agency cited expectations that the company's adjusted debt‑to‑EBITDA ratio will remain below 4.0× over the next 12 months, driven by low single‑digit revenue growth, strong free‑cash‑flow generation and continued debt reduction.
Moody's highlighted several cost‑improvement and operational‑efficiency initiatives that should support margin expansion, including automated workflows, product harmonisation through cloud‑based safety software, and strategic portfolio optimisation. The Ba3 rating is underpinned by ICU Medical's scale, broad product offering, and leading position in the IV infusion therapy market, as well as its high level of recurring consumables revenue and diversified hospital customer base.
The company reported $288 million in cash as of 31 March 2026, and Moody's estimates that it will generate more than $100 million of annual free cash flow over the next 12‑18 months.
Constraints on the rating include the company's modest scale relative to larger competitors, elevated regulatory risk in its infusion‑pump business, and limited pricing power amid hospital budget pressures. The regulatory risk stems from an unresolved FDA warning letter issued in 2025 concerning an inspection of Smiths Medical’s Oakdale, Minnesota facility, which cited device modifications to the MedFusion 4000 and CADD Solis VIP pumps that now require new 510(k) clearances.
Moody's maintained ICU Medical’s Speculative Grade Liquidity Rating at SGL‑1. The firm has a $500 million revolving credit facility that expires in October 2030 and a $150 million accounts‑receivable purchase programme that is not currently being utilised.